Filtered By:
Specialty: Endocrinology
Condition: Diabetes
Countries: Canada Health
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 15 results found since Jan 2013.
Epidemiology of Cerebrovascular Disease among Chinese Canadians with Diabetes
Conclusion Chinese Canadians with diabetes who had ischemic strokes were especially susceptible to intracranial small vessel disease compared with non-Chinese Canadians. These results signify that risk factor prevalence and stroke types differ considerably between Chinese Canadians and non-Chinese Canadians residing in Toronto, warranting further study.
Source: Canadian Journal of Diabetes - May 24, 2017 Category: Endocrinology Source Type: research
Epidemiology of Cerebrovascular Disease Among Chinese Canadian Adults With Type 2 Diabetes
Conclusion Chinese Canadians with diabetes who had ischemic strokes were especially susceptible to intracranial small vessel disease compared with non-Chinese Canadians. These results signify that risk factor prevalence and stroke types differ considerably between Chinese Canadians and non-Chinese Canadians residing in Toronto, warranting further study.
Source: Canadian Journal of Diabetes - February 28, 2018 Category: Endocrinology Source Type: research
Update in Cardiovascular Safety of Incretin-Based Therapy in Adults with Type 2 Diabetes Mellitus: A Meta-Analysis of Cardiovascular Outcome Trials
ConclusionThis meta-analysis demonstrated that GLP-1RAs were associated with a significant reduction in MACE, CV death, stroke, and death from any cause, while DPP-4 inhibitors were comparable to placebo for all CV outcomes, including hospitalizations for HF.
Source: Canadian Journal of Diabetes - April 14, 2019 Category: Endocrinology Source Type: research
Update on Cardiovascular Safety of Incretin-Based Therapy in Adults With Type 2 Diabetes Mellitus: A Meta-Analysis of Cardiovascular Outcome Trials
ConclusionsThis meta-analysis demonstrated that GLP-1RAs were associated with a significant reduction in major adverse CV events, CV death, stroke and death from any cause, while DPP-4 inhibitors were comparable to placebo for all CV outcomes, including hospitalizations for heart failure.RésuméObjectifsLes auteurs de deux grands essais randomisés ont récemment publié leurs conclusions concernant les effets d'un agoniste du récepteur au glucagon-like peptide-1 (A-GLP-1R) (essai HARMONY) et d'un inhibiteur de la dipeptidyl peptidase 4 (DPP-4) (essai CARMELINA) sur les bénéfices cardiovasculaires (CV) chez les patie...
Source: Canadian Journal of Diabetes - June 5, 2019 Category: Endocrinology Source Type: research
The Divergent Cardiovascular Effects of ACE Inhibitors and ARBs in Patient With Type 2 Diabetes Mellitus
Publication date: Available online 22 December 2017 Source:Canadian Journal of Diabetes Author(s): Martin H. Strauss, Alistair S. Hall The renin angiotensin aldosterone system (RAAS) plays a central role in the pathophysiology of hypertension and vascular disease. Angiotensin-converting enzyme inhibitors (ACEi's) suppress angiotensin II (ANG II) concentrations, whereas angiotensin II type 1 (AT1) receptor blockers (ARBs) block the binding of ANG II to AT1 receptors. ACEi's and ARBs are both effective antihypertensive agents and produce similar risk reductions for stroke, a blood pressure-dependent phenomenon. ACEi's also ...
Source: Canadian Journal of Diabetes - December 22, 2017 Category: Endocrinology Source Type: research
Activated Mast Cells Mediate Low-Grade Inflammation in Type 2 Diabetes: IL-37 Could be Beneficial
Publication date: Available online 31 January 2018 Source:Canadian Journal of Diabetes Author(s): Pio Conti, Gianpaolo Ronconi, Spyridon K. Kritas, Alessandro Caraffa, Theoharis C. Theoharides Mast cells (MCs) promote guest immune response against parasites and play a critical role in allergic and inflammatory reactions. Once they have been activated, MCs release high inflammatory compounds that can provoke serious pathological signs that can even lead to death. MCs generate a number of pre-formed, de novo synthesized compounds, and inflammatory cytokine/chemokine synthesis in response to the high affinity (Kd=10-10 M) Ig...
Source: Canadian Journal of Diabetes - February 28, 2018 Category: Endocrinology Source Type: research
The Divergent Cardiovascular Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Type 1 Receptor Blockers in Adult Patients With Type 2 Diabetes Mellitus
Publication date: April 2018 Source:Canadian Journal of Diabetes, Volume 42, Issue 2 Author(s): Martin H. Strauss, Alistair S. Hall The renin angiotensin aldosterone system (RAAS) plays a central role in the pathophysiology of hypertension and vascular disease. Angiotensin-converting enzyme inhibitors (ACEi's) suppress angiotensin II (ANG II) concentrations, whereas angiotensin II type 1 (AT1) receptor blockers (ARBs) block the binding of ANG II to AT1 receptors. ACEi's and ARBs are both effective antihypertensive agents and produce similar risk reductions for stroke, a blood pressure-dependent phenomenon. ACEi's also red...
Source: Canadian Journal of Diabetes - March 28, 2018 Category: Endocrinology Source Type: research
Activated Mast Cells Mediate Low-Grade Inflammation in Type 2 Diabetes: Interleukin-37 Could be Beneficial
Publication date: Available online 31 January 2018Source: Canadian Journal of DiabetesAuthor(s): Pio Conti, Gianpaolo Ronconi, Spyridon K. Kritas, Alessandro Caraffa, Theoharis C. TheoharidesAbstractMast cells (MCs) promote guest immune responses to parasites and play a critical role in allergic and inflammatory reactions. Once they have been activated, MCs release highly inflammatory compounds that can provoke serious pathologic signs that can lead to death. MCs generate a number of preformed, de novo synthesized compounds and inflammatory cytokine/chemokine synthesis in response to the high-affinity (Kd=10–10 M) immuno...
Source: Canadian Journal of Diabetes - July 5, 2018 Category: Endocrinology Source Type: research
The Divergent Cardiovascular Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Type 1 Receptor Blockers in Adult Patients With Type 2 Diabetes Mellitus
Publication date: April 2018Source: Canadian Journal of Diabetes, Volume 42, Issue 2Author(s): Martin H. Strauss, Alistair S. HallAbstractThe renin angiotensin aldosterone system (RAAS) plays a central role in the pathophysiology of hypertension and vascular disease. Angiotensin-converting enzyme inhibitors (ACEi's) suppress angiotensin II (ANG II) concentrations, whereas angiotensin II type 1 (AT1) receptor blockers (ARBs) block the binding of ANG II to AT1 receptors. ACEi's and ARBs are both effective antihypertensive agents and produce similar risk reductions for stroke, a blood pressure-dependent phenomenon. ACEi's als...
Source: Canadian Journal of Diabetes - July 10, 2018 Category: Endocrinology Source Type: research
Activated Mast Cells Mediate Low-Grade Inflammation in Type 2 Diabetes: Interleukin-37 Could be Beneficial
Publication date: Available online 31 January 2018Source: Canadian Journal of DiabetesAuthor(s): Pio Conti, Gianpaolo Ronconi, Spyridon K. Kritas, Alessandro Caraffa, Theoharis C. TheoharidesAbstractMast cells (MCs) promote guest immune responses to parasites and play a critical role in allergic and inflammatory reactions. Once they have been activated, MCs release highly inflammatory compounds that can provoke serious pathologic signs that can lead to death. MCs generate a number of preformed, de novo synthesized compounds and inflammatory cytokine/chemokine synthesis in response to the high-affinity (Kd=10–10 M) immuno...
Source: Canadian Journal of Diabetes - July 10, 2018 Category: Endocrinology Source Type: research
Glucose screening in pregnancy and future risk of cardiovascular disease in women: a retrospective, population-based cohort study
Publication date: Available online 27 March 2019Source: The Lancet Diabetes & EndocrinologyAuthor(s): Ravi Retnakaran, Baiju R ShahSummaryBackgroundIn studies to date, gestational diabetes has consistently been associated with an increased future risk of cardiovascular disease, irrespective of the antepartum screening protocol or diagnostic criteria by which gestational diabetes is diagnosed. We reasoned that the resultant heterogeneity in the severity of dysglycaemia in women with gestational diabetes suggests that the relationship between gestational glycaemia and subsequent cardiovascular disease probably extends into t...
Source: The Lancet Diabetes and Endocrinology - March 28, 2019 Category: Endocrinology Source Type: research
Orexin-A Prevents Lipopolysaccharide-Induced Neuroinflammation at the Level of the Intestinal Barrier
We examined a possible protective effect of OX-A against LPS-induced ROS formation and microglia activation. To mimic in vitro the connection between gut and brain and to study the putative effect on the cortical microglia, we used a co-culture of Caco-2 cells and primary cortical microglia with Caco-2 cells placed at the apical side of a transwell and primary cortical microglia at the basolateral side. All treatments used to study the apical vs. basal connection were applied to the apical compartment. We used DHR (10 μM, 20 min), a cell-permeable fluorogenic probe useful for the detection of ROS formation, to dete...
Source: Frontiers in Endocrinology - April 9, 2019 Category: Endocrinology Source Type: research
The Cardiovascular Effects of SGLT2 Inhibitors
Publication date: Available online 24 September 2019Source: Canadian Journal of DiabetesAuthor(s): Vincent C. WooAbstractIndividuals with type 2 diabetes mellitus can benefit from pharmacotherapies that lower their risk for cardiovascular disease. This review describes the salient findings from sodium-glucose cotransporter-2 (SGLT2) inhibitor cardiovascular outcome trials that serendipitously revealed the cardiorenal benefits of SGLT2 inhibitors in individuals with type 2 diabetes mellitus who either have established cardiovascular disease or multiple cardiovascular risk factors. It also summarizes the findings from other ...
Source: Canadian Journal of Diabetes - November 29, 2019 Category: Endocrinology Source Type: research
Cardiovascular Effects of Sodium-Glucose Cotransporter-2 Inhibitors in Adults With Type 2 Diabetes
Publication date: Available online 24 September 2019Source: Canadian Journal of DiabetesAuthor(s): Vincent C. WooAbstractAdults with type 2 diabetes mellitus can benefit from pharmacotherapies that lower their risk for cardiovascular disease. This review describes the salient findings from sodium-glucose cotransporter-2 (SGLT2) inhibitor cardiovascular outcome trials that serendipitously revealed the cardiorenal benefits of SGLT2 inhibitors in adults with type 2 diabetes mellitus who either have established cardiovascular disease or multiple cardiovascular risk factors. It also summarizes the findings from other phase 3 cl...
Source: Canadian Journal of Diabetes - December 13, 2019 Category: Endocrinology Source Type: research
